• 1
    European Medicines Agency. Pandemrix European Public Assessment Report. Summary of Product Characteristics. 2008; Available at (Accessed 28 May 2009).
  • 2
    International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply International Task Force. Industry provides significant voluntary contributions to global pandemic preparations. 2008; available at (Accessed 28 May 2009).
  • 3
    Ehrlich H, Müller M, Oh H, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:25732584.
  • 4
    Stephenson I, Bugarini R, Nicholson K et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. JID 2005; 191:12101215.
  • 5
    Novartis. Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu. 2008; Company press release, available at (Accessed 28 May 2009).
  • 6
    GlaxoSmithKline. New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning. 2008; Company press release, available at (Accessed 28 May 2008).
  • 7
    Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 298:242249.
  • 8
    Stephenson I, Nicholson K, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:163133.
  • 9
    The Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macroepidemiology of influenza vaccination in 56 countries, 1997–2003. Vaccine 2005; 23:51335143.
  • 10
    The International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply (IFPMA IVS) task force. Influenza Vaccine Distribution in 141 Countries, 2004–2007. 2008; presented at: Third European Influenza Conference. Vilamoura, Portugal, 14–17 September .
  • 11
    Hehme N, Colegate T, Palache B, Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine 2008; 26S:D23D26.
  • 12
    Jacobson SH, Sewell EC, Jokela JA. Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics. Expert Rev Vaccines 2007; 6:981990.
  • 13
    Aaby K, Abbey RL, Herrmann JW, Treadwell M, Jordan CS, Wood K. Embracing computer modelling to address pandemic influenza in the 21st Century. J Public Health Manag Pract 2006; 12:365372.
  • 14
    US Department of Health and Human Services and US Department of Homeland Security. Guidance on allocating and targeting pandemic influenza vaccine. available at (accessed 12 January 2009).